Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Konstantinos Tryfonidis, S. Marreaud, H. Khaled, B. De Valk, J. Vermorken, M. Welnicka-jaskiewicz, K. Aalders, J. M. S. Bartlett, L. Biganzoli, J. Bogaerts, David Cameron

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalBreast cancer research and treatment
Publication statusPublished - 21 Mar 2017

Cite this